Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...

With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China, metabolic dysfunction-associated non-alcoholic fatty liver disease has become the most prevalent ...

Discover how circulating cell-free DNA (cfDNA) is transforming the diagnosis and monitoring of metabolic diseases like ...

The key takeaway? Type 2 diabetes is largely preventable, and in many cases, reversible. By focusing on reducing insulin ...

A new study suggests that beta blockers could reduce fat accumulation in the liver of mice genetically predisposed to ...

Around one in five Brits are thought to be living with this potentially deadly disease, although many may not even realise ...

formerly nonalcoholic fatty liver disease), including 65% of those with type 2 diabetes (T2D) and 75% of those with obesity. At the “Innere Medizin fachübergreifend — Diabetologie grenzenlos ...

Anyone who has tried to lose weight by cutting calories knows the frustration—after initial success, weight loss slows down ...

With changing lifestyles and hectic work schedules, most people today are pressed for time. Meal preparation takes a backseat ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

T2D is the most common form of diabetes, accounting for ... using it to treat non-alcoholic fatty liver disease. The study participants were also type 2 diabetics, which is commonly associated ...